Clinical trial
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in…
NCT00081614 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00081614 |
|---|---|
| Title | A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Metastases |
| Intervention type | Drug |
| Interventions | Avastin (bevacizumab), Tarceva (erlotinib HCl) |
| Enrollment | 100 |
| Start date | Mar 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Apr 20, 2004 |
| Last update posted | May 16, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: